Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Original Article

IL-23 versus IL-12/23 inhibitors in new-onset psoriatic arthritis

Interleukin 23 versus interleukin 12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network.

Journal of the American Academy of Dermatology

Citation & Authors

J Am Acad Dermatol. 2024;91(5):889-895.

Sung Huang Laurent Tsai; Chi-Ya Yang; An-Ping Huo; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

The TriNetX study compared incident psoriatic arthritis in adults with psoriasis receiving IL-23 or IL-12/23 inhibitors. Cumulative incidence did not differ significantly between groups (P=0.812), consistent with the Kaplan–Meier analysis. Although the incidence was numerically lower in the IL-23 group, superiority over IL-12/23 inhibitors has not been established; longer follow-up is needed.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗